Ocugen
974 posts
Ocugen
@Ocugen
Approaching healthcare innovation with ingenuity, passion and courage to create new solutions to difficult medical challenges. Guidelines: bit.ly/3CMYyZW
Hi @ABonTV @NewsNationNow great #morninginamerica interview w/ Dr Fauci today. Just clarifying that we submitted an emergency use authorization (EUA) application for COVAXIN #vaccine candidate to @US_FDA on Nov 5, 2021 for ages 2-18. It’s now under review bit.ly/3sJrxuB
- #BREAKING:@WHO granted Emergency Use Listing approval to #COVID-19 vaccine COVAXIN™, developed by our partner @BharatBiotech. We are pleased this vaccine now has the potential to protect millions more people around the world from severe COVID-19 disease. ow.ly/GVq450GFcqB
- We’re pleased to share that the @US_FDA lifted the clinical hold on our Investigational New Drug (IND) application for our #COVID19 #vaccine candidate. We are eager to move forward! Read more: bit.ly/3LUZ3Fw
- Dr. Anthony Fauci, NIAID Director and Chief Medical Advisor to the President, talked about how #COVAXIN has been found to neutralize the #617variant of the #COVID19 virus. #B1617Variant #DrFauci bit.ly/2QEBlFB
- The B.1.617 variant, which is effectively neutralized by #COVAXIN, has triggered a 2nd wave of #COVID-19 cases rapidly spreading in 17 countries including the US, according to @WHO. For more information, visit: bit.ly/332qnfH.
- Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada bit.ly/3ccA3sQ
- We’ve filed an EUA application with the @US_FDA to seek emergency use authorization of our investigational #COVID-19 vaccine candidate for children ages 2-18 in the US. It is being administered under emergency use authorization in 17 countries. Learn more: ow.ly/4SXe50GGQ72
- We’re pleased to announce that we have expanded our exclusive commercialization rights for our #COVID19 vaccine to Mexico. Already approved for emergency use in adults in Mexico, it’s under review for emergency use in children 2-18. Read more: bit.ly/3uSJs2s
- #BREAKING: New data suggest a #booster dose of our #COVID19 #vaccine candidate generates a robust neutralizing antibody response against both live virus #omicronvariant and #deltavariant. Learn more: bit.ly/3rftcWB
- We’re proud to share that the first patient has been dosed in the Phase 1/2 clinical trial of our modifier #genetherapy candidate for the treatment of #retinitispigmentosa. Find out more about this exciting milestone: bit.ly/3qUy1VM
- We’re pleased to share that the results of our study conducted at @EmoryUniversity showing that a booster dose of our #COVID19 #vaccine candidate neutralizes Omicron and Delta variants are now published on @medrxivpreprint. Read more: bit.ly/32H5KJx
- Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN bit.ly/3yErxMZ
- Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2 bit.ly/3xBTW5X
